Addiction Research Fellowship Program

Addictions and the associated public health problems of HIV transmission, crime and violence, exact a severe toll on our nation, costing billions annually in health care, lost productivity, and incarceration. These inter-related problems have only worsened during the global COVID-19 pandemic, still ongoing. We need to speed the "forward" translation of recent neuroscience and neurogenetic knowledge into more effective clinical treatments for the addictions. Conversely, for addiction treatments with some known efficacy, we can now apply new neuroscience and genetic tools in "backward-translation" -- e.g., finding why a treatment works well for some individuals, yet not at all for others. To help meet the need for skilled translational researchers, this application proposes continuation of a successful (32 total trainees; 16 in the current funding period) NIDA T32 Translational Addiction Research Fellowship at the University of Pennsylvania. The training program (4 pre- and 4 post- doctoral positions) makes explicit a long-standing translational tradition at Penn, integrating clinical and basic research strengths to create trainees, whether clinical or preclinical, Ph.D.s or M.D.s, who will accelerate addiction science in the next decade. The emphasis on translation is reflected at each level of the program - through the Co-PIs (clinical and basic, Drs. Childress and Blendy), the internal and external advisors, the formal didactics, the "dual" (clinical - preclinical) journal clubs, and in the trainees' mentored research projects. The translational emphasis of the program is driven by the recognition that addictions are complex disorders, multi- determined by interaction of genetic vulnerabilities, exposure to drug, and a host of modulating (e.g., early trauma, stress, cultural norms) influences. Trainees are thus offered state-of-the-art knowledge about these interacting determinants through a didactic series specific to the program, and through mentored projects that may range from molecular and genetic studies, to brain systems (neuroscience and neuroimaging, including PET), to clinical treatment trials, and drug policy. This wide range of choices is enabled by the long history of excellence in addiction research at the University, reflected in several interacting academic research entities (Penn Center for Studies on Addiction; Translational Research Laboratories/CNB; Center for AIDS Research; Penn PET Center; the Complex Systems Lab) offering skilled, successful mentors to the Fellowship. Mentored research also takes place within several affiliated treatment settings (VA, Presby-Penn, local opioid treatment clinics, and mobile HIV Prevention units), critical for translating new research findings into the "real world”.

Public Health Relevance Statement

The proposed continuation of a recently-funded T32 Translational Addiction Research Fellowship at the University of Pennsylvania will give 4 pre-doctoral and 4 post-doctoral trainees the framework, and the skills, to speed the next generation of effective addiction treatments – with concomitant benefit for the addiction-linked public health problems of violence, crime and HIV/AIDs.

Click here to learn more.

CONTACT

Anna Rose Childress, Ph.D.
Research Professor, Adj. and 
Director, Brain-Behavioral Vulnerabilities Laboratory
Center for Studies of Addiction
Department of Psychiatry
University of Pennsylvania Perelman School of Medicine
Email: childress@pennmedicine.upenn.edu

Back to Top